×
About 38,313 results

ALLMedicine™ Acute Myeloid Leukemia Center

Research & Reviews  11,959 results

Immunohistochemical Staining to Identify Concomitant Systemic Mastocytosis in Acute Mye...
https://doi.org/10.3343/alm.2022.42.6.678
Annals of Laboratory Medicine; Hwang SM, Kim BJ et. al.

Jun 30th, 2022 - Systemic mastocytosis with associated hematological neoplasm (SM-AHN) poses diagnostic challenges because of the coexistence of atypical mast cell proliferation and hematological neoplasms. We assessed the presence of SM-AHN in patients with acute...

Degradation of GSPT1 causes TP53-independent cell death in leukemia whilst sparing norm...
https://doi.org/10.1172/JCI153514
The Journal of Clinical Investigation; Sellar RS, Sperling AS et. al.

Jun 29th, 2022 - Targeted protein degradation is a rapidly advancing and expanding therapeutic approach. Drugs that degrade GSPT1 via the CRL4CRBN ubiquitin ligase are a new class of cancer therapy in active clinical development with evidence of activity against a...

HERVs characterize normal and leukemia stem cells and represent a source of shared epit...
https://doi.org/10.1002/ajh.26647
American Journal of Hematology; Alcazer V, Bonaventura P et. al.

Jun 28th, 2022 - Human endogenous retroviruses (HERVs) represent 8% of the human genome. The expression of HERVs and their immune impact have not been extensively studied in Acute Myeloid Leukemia (AML). In this study, we used a reference of 14,968 HERV functional...

CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With...
https://doi.org/10.1016/j.clml.2022.06.001
Clinical Lymphoma, Myeloma & Leukemia; Lee D, Jain AG et. al.

Jun 28th, 2022 - CPX-351 was approved by the FDA in 2017 as frontline induction chemotherapy for patients aged ≥18 years with newly diagnosed acute myeloid leukemia (AML) which includes myelodysplasia-related changes (AML-MRC) and therapy-related acute myeloid leu...

see more →

Guidelines  12 results

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
https://doi.org/10.6004/jnccn.2021.0002
Journal of the National Comprehensive Cancer Network : JN... Pollyea DA, Bixby D et. al.

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients W...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499615
Journal of Clinical Oncology : Official Journal of the Am... Lehrnbecher T, Fisher BT et. al.

May 28th, 2020 - To develop a clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation (HSCT) recipients. Recommendations were developed by an international multidisciplinary pane...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0116
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

see more →

Drugs  30 results see all →

Clinicaltrials.gov  1,665 results

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
https://clinicaltrials.gov/ct2/show/NCT04401748

Jun 24th, 2022 - Myelodysplastic Syndrome (MDS) is a group of disorders that gradually affect the ability of a person's bone marrow (semi-liquid tissue present in many bones like backbones) to produce normal blood cells. Some people with MDS have a risk of the dis...

A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
https://clinicaltrials.gov/ct2/show/NCT03730012

Jun 24th, 2022 - This study was planned to have 2 phases: Phase 1: The phase 1 portion of this study was to establish the recommended phase 2 dose (RP2D) of gilteritinib given in combination with atezolizumab. Phase 2: The phase 2 portion of the study was to treat...

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
https://clinicaltrials.gov/ct2/show/NCT02993523

Jun 24th, 2022 - Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). Successful treatment of AML is dependent on what subtype of AML the participant has, and the age of the parti...

BMS-986253 in Myelodysplastic Syndromes
https://clinicaltrials.gov/ct2/show/NCT05148234

Jun 24th, 2022 - Background: The myelodysplastic syndromes (MDS) are a group of clonal bone marrow neoplasms characterized by ineffective hematopoiesis, cytopenia, and high risk for transformation to acute myeloid leukemia (AML). MDS is primarily a disease of the ...

Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
https://clinicaltrials.gov/ct2/show/NCT05431257

Jun 24th, 2022 - Multi-center phase II study of standard azacytidine treatment (AZA; D1-D7, 75mg/m2 qd) in combination with a short duration of "low-dose" venetoclax treatment (LD-VEN; D1-D14 before CR and D1-D7 after CR, 400mg qd) per 28 days cycle for elderly/un...

see more →

News  1,653 results

No Survival Gain From High-Dose Cytarabine Consolidation in AML
https://www.medscape.com/viewarticle/976065

Jun 23rd, 2022 - The study was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway Regarding consolidation therapy for younger patients with acute myeloid leukemia (AML), there was no survival benefit from taking high-dos...

Adverse-Risk Acute Myeloid Leukemia
https://www.medscape.com/viewarticle/964535

Jun 16th, 2022 - This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz, I'm a professor of medicine. I run the leukemia program at Weill Cornell Medicine at the NewYork-Presbyterian Hospital in New York City. It is ...

Quizartinib Doubles Overall Survival in FLT3-ITD-Positive AML
https://www.medscape.com/viewarticle/975457

Jun 13th, 2022 - The potent oral FLT3 inhibitor quizartinib more than doubled overall survival among patients newly diagnosed with FLT3-ITD-positive acute myeloid leukemia (AML) compared with standard chemotherapy, new phase 3 data show. Among adults who received ...

Similar Survival, Less Toxicity With Decitabine vs Chemo in AML
https://www.medscape.com/viewarticle/975438

Jun 12th, 2022 - Older, fit patients with acute myeloid leukemia (AML) pretreated with a 10-day regimen of decitabine (Dacogen) prior to allogeneic hematopoietic stem cell transplantation had similar overall survival compared with those receiving conventional inte...

Intermediate-Risk Acute Myeloid Leukemia
https://www.medscape.com/viewarticle/964532

May 19th, 2022 - This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and the NewYork-Presbyterian Hospital in New York Ci...

see more →

Patient Education  6 results see all →